ReIGNITE is harnessing the power of directed evolution for the precise in vivo delivery of oncolytic immunotherapies and gene therapies.
ReIGNITE’s complimentary dual viral vector platforms are engineered using directed evolution for the targeted in vivo delivery of oncolytic immunotherapies and gene therapies.
Genetic therapies hold immense promise to treat, and even cure, some of the most challenging diseases. Yet, despite groundbreaking advances in gene editing and sequencing, one major obstacle stands in the way: the safe and effective delivery of genetic material to target cells.
At ReIGNITE, we believe the future of genetic therapy hinges on solving these delivery problems. Our proprietary approach focuses on engineering viral vectors using directed evolution to overcome some of the biggest limitations facing the sector today. Learn More about our InViroMax Platform below.
By harnessing our expertise in directed evolution, we are ushering in a new era of genetic medicines by offering systemic, safe and high-capacity viral vectors for oncoloytic immunotherapies and gene therapies
Our platform is designed to deliver large payloads of genetic material and gene editing constructs, with a capacity of up to 50 kB.
Our vectors are engineered to include tissue-specific promoters, enabling endogenous regulation.
Our viruses are engineered for efficient IV delivery targeting solid tumors, metastatic cancer, and monogenic genetic diseases.
Join us as we push the boundaries of what’s possible with genetic therapy and transform treatment outcomes for patients.
